Replies to post #16036 on Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

In relation to point 4: a large number of the woman treated on the AXAL GOG trial were heavily pretreated patients of which I believe around 50% were already previously treated with Avastin (Bevacizumab), which had failed.

In grand scheme of things this is significant.

[mpreorder]

More than 1 PIII will NOT be required. That was the whole reason for the SPA.

[Traderbx]

Meishairwin.. I still think that you are understanding ADXS true present worth...

What do you have to say about that phase 1/2 an*l cancer study which CURED ALL OF THE PATIENTS, complete response?

--------------------------------

COG 0265 achieved 38.5% 12-month survival rate. Only 20% was needed to move forward.

Competition to COG 0265 (Avastin) has only 30% 12-month survival rate.

Phase 1/2 an*l cancer study (BrUOG) has ALL PATIENTS WHO COMPLETED TREATMENT ACHIEVED COMPLETE RESPONSE (CURED)

Phase 1 Study in Canine Osteosarcoma: 78% survival 1-year and 67% survival 2-year (historical standard is 55% 1-year and 28% 2-year)